FIH Partners advises Novo A/S on the

Acquisition of Sonion

Learn more

Healthcare and Medtech

Since the dawn of biotech IPOs in Denmark in the mid-1990s, the partners of FIH Partners have been actively advising pharma, medtech, biotech and medical supplies companies.

Over the years we have developed a deep understanding of the main drivers and risks associated with operating in the sector.

Examples of our experience in healthcare:

  • Advisor to Novo A/S in the acquisition of Sonion, a global leader in micro acoustic technologies used for hearing instruments, for in-ear earphones and in specialty headsets, from Altor Fund III. 
  • Advisor to Ambu, listed on the OMX Nordic exchange, in the acquisition of King Systems a US subsidiary of UK listed Consort Medical. 
  • Advisor to ALK Abello in the acquisition of Artu Biologicals from Dutch listed company Fornix BioSciences.
  • Advisor to Altor Equity Partners in the acquisition of Pulse Medtech from US-based Technitrol.
  • The partners of FIH Partners advised AP Møller Maersk on the divestment of Maersk Medical (Unomedical) to Nordic Capital.
  • The partners advised the majority shareholder and board of Radiometer in the divestment of the company to US-based Danaher Corporation.
  • Also, the partners advised on the IPOs of NeuroSearch, Bavarian Nordic, Genmab and Pharmexa.
 

Selected references

Glycom's acquisition of Vitalys' manufacturing facility

FIH Partners acted as exclusive financial advisor to Glycom on the acquisition of Vitalys' manufacturing facility

Deal value:
Not disclosed

Learn more

Acquisition of Sonion

FIH Partners advised Novo A/S on the acquisition of Sonion

 

Deal value:
Not disclosed

Learn more

Altor Fund III' acquisition of Pulse Medtech

FIH Partners advised Altor Fund III (“Altor”) on the acquisition of Pulse Medtech from Technitrol, Inc.

Deal value:
Not disclosed

Learn more

Acquisition of Artu Biologicals

FIH Partners advised ALK (OMX:ALK B) on the acquisition of Artu Biologicals from Fornix BioSciences (XAMS:FORBI)

Deal value:
Not disclosed

Learn more